BioNexus Gene Lab Corp (BGLC) concluded trading on Wednesday at a closing price of $0.32, with 10.36 million shares of worth about $3.32 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -22.97% during that period and on March 26, 2025 the price saw a gain of about 12.80%. Currently the company’s common shares owned by public are about 17.97M shares, out of which, 11.03M shares are available for trading.
Stock saw a price change of 3.56% in past 5 days and over the past one month there was a price change of -12.06%. Year-to-date (YTD), BGLC shares are showing a performance of 14.41% which decreased to -55.86% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.21 but also hit the highest price of $1.00 during that period. The average intraday trading volume for BioNexus Gene Lab Corp shares is 3.69 million. The stock is currently trading -2.53% below its 20-day simple moving average (SMA20), while that difference is down -10.02% for SMA50 and it goes to -17.33% lower than SMA200.
BioNexus Gene Lab Corp (NASDAQ: BGLC) currently have 17.97M outstanding shares and institutions hold larger chunk of about 0.99% of that.
The stock has a current market capitalization of $5.75M and its 3Y-monthly beta is at 1.70. It has posted earnings per share of -$0.05 in the same period. It has Quick Ratio of 3.99 while making debt-to-equity ratio of 0.02. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BGLC, volatility over the week remained 6.36% while standing at 8.98% over the month.
